Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Picodya Technologies
Picodya Technologies Overview
Healthcare is shifting outside the hospital. However, 80% of the $130B worldwide IVD market (2027) is still conducted at central labs. As current point of care solutions are expensive, limited and don’t meet performance threshold there is a need in the market for fast, reliable, affordable point of care diagnostics to improve care quality and patient experience.
Picodya's B-Matrix, microfluidic lab-on-a-chip platform redefines diagnostics, supports simultaneous hybrid testing for both molecular and immunoassays with multiplexed syndromic panels for various sample types. Our innovative multi-use consumables utilization allows for massive cost reduction while the minimal sample volume offers less invasive patients’ experience.
The system unique and modular design supports diverse clinical settings anywhere from a large hospital systems’ laboratory through urgent care settings and physician offices as well as emerging settings such as airports, pharmacies and patients’ homes.
Our go-to-market approach consists of three main vectors: First – widening our install-base at research use (only) settings, for the purpose of generating a revenue stream, prior to receiving regulatory approvals. Second – following Regulatory approvals within the next 2 years we plan to launch commercial diagnostic panels, providing syndromic diagnostics at every care setting. Our third, longer term effort is co-development of novel diagnostic tests with leading researchers. We already have 3 signed licensing agreements in fields like prostate cancer screening, oncology and companion diagnostics.